Vonoprazan


Vonoprazan is a first-in-class potassium-competitive acid blocker. It was approved in the Japanese market in February 2015.
Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.